Business
Ketamine One Subsidiary KGK Science Becomes the First Founding Sponsor of the “Psychedelic Science 2023” Event
Ketamine One Subsidiary KGK Science Becomes the First Founding Sponsor of the “Psychedelic Science 2023” Event.
About this update from Wellbeing Digital Sciences Inc.
[{"type":"text","content":"\n VANCOUVER, British Columbia, Jan. 10, 2022 (GLOBE NEWSWIRE) -- KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to announce that its wholly-owned contract research organization, KGK Science Inc. (“KGK” or the “CRO”), has become the first founding sponsor of the Psychedelic Science 2023 event (“Psychedelic Science 2023”). Taking place June 19-25, 2023 in Denver, Colorado with an estimated 10,000 attendees, Psychedelic Science 2023 will be the world’s largest gathering of the psychedelic ecosystem. The event will be hosted by Multidisciplinary Association for Psychedelic Studies (“MAPS”) and is being organized by Momentum Events. Psychedelic Science 2023 will feature three days of panels, workshops, and lectures from leaders and visionaries from psychedelic research, education, policy, business, culture, and communities. Conference tracks will be complemented by pre- and post-conference workshops; an exhibit hall; and a marketplace featuring artists, musicians, and other vendors from around the world. Attendees will include MAPS members, donors, researchers, students, clinicians, advocates, therapists, political leaders, entrepreneurs, executives, investors, psychedelic enthusiasts, and those who may benefit from MAPS’ decades of research and advocacy. Additionally, Ketamine One has granted 200,000 stock options (the “Options”) to a director of the Company, 1,901,402 restricted share units (the “RSUs”) to arm’s length advisors, and 150,000 common share purchase warrants (the “Performance Warrants”) to consultants to the Company. Each Option is exercisable to purchase one common share of the Company at a price of $0.27 per common share for a period of five years from the date of grant, in accordance with the Company’s stock option plan. The RSUs were issued pursuant to the Company’s restricted share unit plan approved by shareholders on Feb. 21, 2021. Fifty per cent of the RSUs vest six months from the date of grant, with the remaining fifty per cent of the RSUs vesting 12 months after the date of the grant. Each...